Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q4 2025 Earnings Presentation
18 slides from Inovio Pharmaceuticals's earnings presentation, Mar 12, 2026
Slide 1: Fourth Quarter & Full Year 2025 Financial Results
Fourth Quarter & Full Year 2025 Financial Results March 2026
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer INO-3107 Update Michael Sumner, MBBS, MBA, Chief Medical Officer Steve Egge, MBA, Chief Commercial Officer Pipeline Update Jacqueline Shea, PhD,
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: Strategic Update 2026
2026 BLA for INO-3107 Strategic • Accepted for review under accelerated approval program Dec 2025 Update • Standard review schedule, PDUFA date Oct 30, 2026 • Requested meeting with FDA to discuss preliminary comments in file acceptance letter on accelerated approval eligibility Commercialization Pr
Slide 5: Lead Candidate: INO-3107 for Recurrent Respiratory Papillomatosis (RRP)
LEAD CANDIDATE: INO-3107 for Recurrent Respiratory Papillomatosis (RRP) Potentially transformational therapy under accelerated approval program
Slide 6: Regulatory Update for INO-3107 – Awaiting FDA Meeting
Regulatory Update for INO-3107 – Awaiting FDA Meeting 2025 2026 OCTOBER DECEMBER JANUARY FEBRUARY OCTOBER Completed rolling BLA accepted FDA agreed to Updated IND for October 30, 2026: submission of BLA for review under meeting to confirmatory trial PDUFA target date under Accelerated AA program, di
Slide 7: Accelerated Approval: We Believe INO-3107 Meets FDA Criteria
INO-3107 Accelerated Approval: We Believe INO-3107 Meets FDA Criteria* Meaningful therapeutic benefit Potential to meet remaining over existing treatments critical unmet need EFFICACY SAFETY DIFFERENTIATED MOA • 50% - 100% reduction • No required minimal residual • Ability to treat patients in surge
Slide 8: The Risks and Costs of RRP
INO-3107 Psychological trauma The Risks and Costs of RRP from repeated invasive surgeries/procedures Potential for irreversible damage to vocal cords, bleeding, infection Anxiety, frustration, depression due to quality of voice Missing work, school or social events because of symptoms, Travel cost a
Slide 9: Market Research Highlights Key Strengths vs. Recently Approved Product
INO-3107 Market Research Highlights Key Strengths vs. Recently Approved Product EFFICACY TOLERABILITY SIMPLICITY Improving response over time Well tolerated Patient-centric treatment • Overall Response Rate (50% to • 41% (13/32) reported treatment- • Office-based administration that 100% reduction i
Slide 10: Advancing Launch Preparations
INO-3107 Advancing Launch Preparations Key Market Research and Planning: 300-400 laryngologists • Continued critical research with payers treat the majority of RRP patients and completed research supporting a positively differentiated product profile • Developed pricing strategy with price optimizat
Slide 11: Pipeline Update
Pipeline Update
Slide 12: Advancing our DNA Medicine Platform
Advancing our DNA Medicine Platform DMAb candidate continues to exhibit long-lasting in vivo antibody production • Further analysis in Phase 1 proof-of-concept trial demonstrated DMAb levels remained stable for 96 weeks in all participants reaching that timepoint Building on next-gen technology with
Slide 13: Fourth Quarter & Full Year 2025 Financial Update
Fourth Quarter & Full Year 2025 Financial Update
Slide 14: Achieving Strategic Goals While Reducing Costs
Achieving Strategic Goals While Reducing Costs THREE MONTHS YEAR ENDED DECEMBER 31, 2025 ENDED DECEMBER 31, 2025 % % 2025 2024 CHANGE 2025 2024 CHANGE Operating expenses $17.5 $20.5 (15%) $86.9 $112.6 (23%) Net income (loss) $3.8 ($19.4) 120% $(84.9) ($107.3) 21% Basic net income (loss) per share $0
Slide 15: Q&A
Q&A
Slide 16: Progressing Strategy to Unlock the Promise of DNA Medicine
Progressing Strategy to Unlock the Promise of DNA Medicine NEAR TERM MID TERM NEXTGEN Working to Deliver Advancing Diversified Innovating NextGen INO-3107 to Patients Clinical Pipeline DNA Medicines • BLA accepted for review under accelerated • Additional clinical candidate partnerships, • DMAbs: ap
Slide 17: Quote from RRP Foundation President on BLA submission
“ Every patient deserves a therapy that works for them. I believe we are now one step closer to surgery being a last resort for the treatment of this disease.” Kim McClellan, President of the RRP Foundation, on the completed BLA submission for INO-3107 17
Slide 18: Contact: investor.relations@inovio.com
Contact: investor.relations@inovio.com
Inovio Pharmaceuticals — Q4 2025 Earnings Presentation on 6ix